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Abstract 
 
 
 
 
 
By Rick Kishore Chainani 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
 
Virginia Commonwealth University, 2013. 
 
 
Major Director:  John R. Grider, Professor, Department of Physiology and Biophysics 
 
  
 
 The enteric nervous system controls the gut through the release of specific 
neurotransmitter and neuromodulators at specific sites such as mucosal secretory cell or smooth 
muscle cell. In the present study, we have examined the response to one of these neurohumoral 
agents, Neurotensin, in the rat distal colon. Neurotensin is a paracrine and endocrine modulator 
of the digestive tract. Even though these effects have been seen in colonic preparations, there are 
very few functional studies of the effects of Neurotensin in the rat colon, especially the distal 
colon.  
 In the current study we propose the following hypothesis that Neurotensin will lead to 
contractile effect on basal tone and phasic contraction in the distal rat colon and will mediate this 
process primarily through the NT1 receptor. This hypothesis is based on evidence from the 
mixed action of Neurotensin in other regions of the gut and the more widespread distribution of 
the NT1 receptor. We have identified two specific aims to investigate this hypothesis. 
Aim 1 is to investigate the role of Neurotensin in tonic contraction and phasic contraction of the 
distal rat colon. In this aim, we will expose distal rat colon strips to varying doses of Neurotensin 
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and record changes in basal tone and phasic activity. For our second aim, we will investigate the 
receptors mediating these responses to Neurotensin. In this aim, we will introduce NT1, NT2, 
and nonspecific inhibitors to distal rat colon and observe modulation in Neurotensin effects. We 
will also determine the existence of the receptors via Western Blot. 
 The rat distal colon did respond in a dose-response fashion to varying doses of 
Neurotensin, but elicited different effects dependent on the strip preparation. When the mucosa 
was intact, circular muscle responded with an inhibitory effect to phasic activity, but there was 
little to no change in tonic activity. When the mucosa was removed, the circular muscle 
responded to Neurotensin by eliciting an increase in tonic activity, but had no effect on phasic 
activity.  
 The use of SR48692, a specific NT1 receptor inhibitor, showed that the effects that were 
observed due to Neurotensin were not mediated through the NT1 receptor. With the use of 
SR142948, a non-selective NT1/NT2 inhibitor, the effects of Neurotensin was completely 
abolished. This led us to believe that the observed effects were mediated through a Neurotensin 
receptor and that receptor is likely the NT2 receptor. This was confirmed by the use of the 
specific NT2 receptor antagonist, levocabastine.  
 The existence of the receptor in rat colon had to be confirmed in order to ensure that the 
effects observed were mediated through the NT2 receptor and not from an outside mediator. 
Western Blot analysis confirmed the existence of the NT2 receptor within the mucosa, within the 
muscle, and within the intact preparation of the distal rat colon. Although these results conflict 
with our hypothesis, it provides for an interesting template and avenue of exploration.  
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Introduction and Background 
 
 
 
 
 
 
1.1 Function of Gut  
The gut is a muscular tube that organizes the integrated response to a meal and represents 
a complex set of regulated gastrointestinal, secretory, and motor behaviors designed to perform 
digestion and absorption of a meal and elimination of wastes. These secretory and motor 
behaviors are regulated by neural, hormonal, and paracrine signaling responses. (Pandol 2009). 
These processes are aided by smooth muscle that functions in mixing and propelling intestinal 
contents through the gut. This propulsion is termed peristalsis. 
 
 
1.2 Gut Anatomy 
The innermost layer of the gut is the mucosa, containing both the epithelial cells 
necessary for final digestion and assimilation of the ingested material. The mucosal layer also 
possesses glands able to secrete substances into the gut lumen, cells with sensory capabilities, 
and the muscularis mucosa, a thin layer of smooth muscle that aids in enhanced contact of the 
epithelium with luminal contents as a result of its contractile function. Outside of the mucosal 
layer lies the submucosa, another layer of connective tissue that possesses connections to the 
vasculature, inflammatory cells, and in some cases, glands. The submucosa contains a neural 
plexus, the submucosal plexus which has interconnections within the nervous system of the gut 
(enteric nervous system), as well as connections to the autonomic nervous system. This 
submucosal plexus is important in controlling the secretory functions of the mucosa through 
innervation of the epithelium, and may play a role in the coordination of muscularis mucosae and 
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muscularis externa activity with secretory activity (Rubin 2009). External to the submucosa is 
the circular muscle layer, a layer of smooth muscle cells oriented circumferentially to the central 
axis of the gut lumen (Kunze 1999). Continuing outward, the adjacent layer, known as the 
myenteric plexus, contains neurons and organized connections among these neurons within the 
enteric nervous system, as well as external connections to the autonomic nervous system. This 
layer controls the muscular activity of the circular muscle layer beneath it, and the longitudinal 
muscle layer above it (Kunze 1999). The longitudinal muscle layer consists of smooth muscle 
cells oriented in parallel with the long axis of the lumen. When longitudinal muscle contracts, the 
lumen of the gut is dilated at the contraction site and the gut shortened, in contrast to the actions 
of the circular muscle. The neural connections provided by the myenteric plexus between the 
longitudinal and circular muscle layers coordinate activity to ensure that longitudinal muscle and 
circular muscle do not contract at the same location and at the same time (Grider 1998). Beyond 
the longitudinal muscle layer there exists the serosa, which serves as an outer containment 
membrane for the gut tube. A depiction of these layers are pictured in Figure 1.  
 
 
1.3 Peristalsis  
The intestinal peristaltic reflex consists of ascending and descending phases during which 
circular and longitudinal muscle responds in reciprocal fashion. In circular muscle, the 
orad  contraction  is  mediated  by excitatory motoneurons containing  acetylcholine  and/or 
the  tachykinins  substance  P  and  neurokinin  A , whereas  the  caudad  relaxation  is mediated 
by inhibitory motoneurons containing vasoactive intestinal peptide (VIP) or pituitary adenylate 
cyclase-activating peptide (PACAP) and nitric oxide synthase (NOS). The reflex can be initiated 
by circular muscle stretch and mucosal stimulation. (Grider, Kuemmerle 1996). The circular 
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muscle layer has its long axis oriented as the circumference around the gut tube whereas the 
longitudinal muscle is orientated orad to anal. This organization of muscle layers can be seen in 
Figure 1.  
 
 
1.4 Gut as Agent of Digestion/Absorption/Defense 
As food and drink are ingested, regions of the gut play specific roles in the mechanical 
and chemical breakdown of food. Mechanically, the muscular tube can collapse upon its 
contents, physically compressing them to render the contents into smaller pieces, leading to a 
mixture of the various ingested substances. Chemically, the gut releases agents into its lumen, 
where mixing with the contents leads to chemical reactions that reduce large molecules such as 
starches, proteins, and triglycerides into smaller constitutive pieces such as sugars, peptides, fatty 
acids (Nagler-Anderson 2001). The gut itself possesses sensory functions upon its exposure to 
contents of a meal. Such sensory cells can feed into a control network that manipulates motility, 
secretory, and absorptive behaviors (Kokrashvili 1999) (Egan1998). 
 
 
1.5 The Enteric Nervous System and Neurotransmitters 
Thus, the gut performs many functions and is composed of many cell and tissue 
types.  The adequate regulation of gut function depends on control of all these different 
functions.  To maintain control, the gut uses a variety of mechanisms: (1) mucosal paracrine cells 
that secrete active agents locally, (2) hormones that are secreted into the blood and affect other 
regions of the gut as well as other organ systems and (3) the enteric nervous system and its 
connections to the autonomic nervous system.  The enteric nervous system controls the gut 
through the release of specific neurotransmitter and neuromodulators at specific sites such as 
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mucosal secretory cell or smooth muscle cell.  The number of neurotransmitters has been 
estimated to be over 30 different types allowing for a variety of responses depending on the 
transmitter released.  One characteristic of enteric neurons is that often one neuron can release 
more than one neurotransmitter and certain neurotransmitters can be assigned specific 
functions.  As noted above, excitatory motor neurons which innervate smooth muscle release 
acetylcholine and a tachykinin, substance P to cause contraction whereas inhibitory motor 
neurons release VIP, PACAP and NO.  Sensory neurons release calcitonin gene-related peptide 
(CGRP) and Substance P.   Most of the other neurotransmitters are contained in interneurons that 
connect the motor and sensory neurons together in reflex arc or are contained in other neurons 
that innervate the mucosa and smooth muscle as secondary motor neurons.  The role of these 
other neurotransmitters is much less well known.  Many of the neurotransmitters have a dual 
presence and function, being contained also in the paracrine and hormonal cells of the 
mucosa.  Even less is known of the role of these neurohumoral agents. In the present study, we 
have examined the response to one of these neurohumoral agents, Neurotensin. (Furness 2008) 
(Furness 2004) 
 
 
1.6 Neurotensin 
 Neurotensin is a 13 amino acid peptide originally isolated from bovine hypothalamus but 
it was subsequently found to be widely distributed in the gastrointestinal tract (Polak 1977). 
Neurotensin is a neuromodulator of dopamine transmission and of anterior pituitary hormone 
secretion, and exerts potent hypothermic and analgesic effects in the brain. NT has been shown 
to modulate dopaminergic transmission in the nigrostriatal and mesocorticolimbic pathways, 
thereby implicating this neuropeptide in the pathophysiology of several central nervous system 
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disorders, including Parkinson’s disease and schizophrenia (Gendron 2004). In the periphery, 
Neurotensin is a paracrine and endocrine modulator of the digestive tract and of the 
cardiovascular system of mammals and acts as a growth factor on a variety of normal or cancer 
cells. (Vincent 1999).  Thus Neurotensin can be a neurotransmitter in the central nervous system 
and a paracrine/endocrine agent in the gut.  In examining the colon, Neurotensin has been shown 
to be involved in the stimulation of colonic motor activity in the canine species (Bardon et al 
1984). Augeron also reported that Neurotensin stimulates mucin secretion from human colon 
goblet cell line by receptor mediated mechanism (Augeron 1992). Neurotensin has been 
shown  to  relax the rat duodenum, the  rat  ileum  and  the  guinea-pig  proximal  colon, 
and  to  contract  the  rat  stomach  strip, the guinea- pig taenia coli and the human colon 
(Couture et al., 1981).  Neurotensin has also been shown to cause inhibition of the spontaneous 
contractile activity of the rabbit isolated colon and to produce a biphasic response in the guinea-
pig ileum (Fontaine et al 1985). Even though these effects have been seen in colonic 
preparations, there are very few functional studies of the effects of Neurotensin in the rat colon, 
especially the distal colon.  
 
 
1.7 Neurotensin Receptors 
 The first Neurotensin receptor was cloned in 1990 by Nakanishi and his group and it was 
dubbed the NTS1 for the Neurotensin 1 Receptor (referred to as NT1 throughout the paper). This 
receptor was found to belong to the G-protein coupled receptor family with the first receptor 
antagonist of the receptor, SR48692, developed a year later (Tanaka 1990). Tanaka’s group also 
found that the NT1 receptor was found distributed throughout the brain and the intestine of rat 
and humans. From the binding data, it was evident that there was a high affinity binding site that 
15	  
	  
was insensitive to the putative antagonist Levocabastine, but there was also a low affinity 
binding site that was able to be selectively blocked with this drug. Levocabastine is an 
antihistamine-1 drug that is devoid of any Neurotensin-like pharmacological properties and 
selectively blocks the lower affinity binding site without changing the binding properties of the 
higher-affinity sites (Shotte 1986) (Kitabgi 1987). This receptor site was cloned and named the 
NTS2 receptor and is also a G-protein coupled receptor that retains a 64% sequence homology to 
the NT1 receptor (referred to as NT2 Receptor throughout the paper) (Chalon 1996) (Vincent et 
al 1999).  This finding allows Levocabastine to be used as an NT2 receptor antagonist. The 
putative antagonist SR142948 compound was found to recognize receptors of both species with 
even higher affinities than their selective antagonist counterparts, making SR142948 useful as a 
broad antagonist of both NT receptors while distinguishing Neurotensin mediated responses 
from those mediated by other agents and receptors. (Gully 1997) (Chalon 1996). Xenopus 
oocytes transfected with the mouse NT2 receptor respond to NT by induction of a Ca2-
dependent Cl- current, but the amplitude of the current is 10-100 times smaller than that induced 
by Neurotensin on NT1 receptor injected oocytes suggesting that the NT1 receptor would be 
more responsible for physiological induced changes (Mazella 1996).  
 
 
1.8 Neurotensin Receptor Locations 
 Northern blot analysis has shown that the NT2 receptor mRNA is expressed mostly in the 
brain (Chalon 1996) (Mazella 1996) which differs from the NT1 receptor distribution that is 
more evenly distributed within the brain and the periphery in mice and rats. A table summarizing 
these two receptors is presented in Table 1.  
1.9 NT3/Sortilin 
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 A structurally unrelated receptor, the NT3/Sortilin receptor, is a type I amino acid 
receptor with a single transmembrane region that is located intracellularly (Mazella 1998). This 
receptor has only been found in human cell types and has 100% homology to the Sortilin protein 
found in humans that is involved in the sorting of receptors and is identified by its ability to 
interact with receptor-associated protein (Vincent et al 1999). Sortilin is a very promiscuous 
receptor and is known to form complexes with many other receptors. In general, it is thought that 
Sortilin acts as a clearance receptor to remove these other receptors from the cell surface or to 
modulate their activity.  It is also generally thought that sortilin, by itself, does not signal and has 
no non-clearance function although this notion is just beginning to be challenged. Due to these 
characteristics, and the fact that there is no commercially available receptor antagonists of the 
NT3 receptor currently, no experiments were conducted with the NT3 receptor (Nykjaer 2012) 
(Mazella 2001).  
 
 
1.10 Hypothesis and Specific Aims 
In the current study we propose the following hypothesis that Neurotensin will lead to 
contractile effect on basal tone and phasic contraction in the distal rat colon and will mediate this 
process primarily through the NT1 receptor. This hypothesis is based on evidence from the 
mixed action of Neurotensin in other regions of the gut and the more widespread distribution of 
the NT1 receptor. We have identified two specific aims to investigate this hypothesis. 
Aim 1 is to investigate the role of Neurotensin in tonic contraction and phasic contraction 
of the distal rat colon. In this aim, we will expose distal rat colon strips to varying doses of 
Neurotensin and record changes in basal tone and phasic activity. 
17	  
	  
 For our second aim, we will investigate the receptors mediating these responses to 
Neurotensin. In this aim, we will introduce NT1, NT2, and nonspecific inhibitors to distal rat 
colon and observe modulation in Neurotensin effects. We will also determine the existence of the 
receptors via Western Blot.  
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Figure 1: The anatomical organization of the wall of the gastrointestinal tract. Adapted from 
Furness and Costa (1987), The Enteric Nervous System 
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Table 1: Summary of Neurotensin Receptor Subtypes. Adapted from Hermans and Malateaux 
(1998), Mechanism of regulation of Neurotensin receptors 
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Materials and Methods 
 
 
2.1 Animal Preparation 
 Rats were euthanized by CO2 asphyxiation under protocols approved by the Institutional 
Animal Care and Use Committee of VCU. The colon was dissected out, emptied of contents and 
placed in a warmed (37°C) oxygenated Krebs solution of the following composition (in mM): 
118 NaCl, 4.75 KCl, 1.19 KH2PO4, 1.2 MgSO4, 2.54 CaCl2, 25 NaHCO3, 11 mM glucose (pH 
7.4). 2-3 cm long sections of distal colon and proximal colon were removed and pinned in a Petri 
dish warmed by circulating (37°C) water and filled with warmed (37°C) Krebs solution. The 
resultant section of colon was freed of excess fat and mesenteric attachments and held in 
oxygenated Krebs buffer until use for tension recording or molecular assay.  Normally the time 
from removal to use in experimental protocol did not exceed 30 minutes.  A muscle strip was 
prepared from the colonic segment by opening the segment along the mesenteric attachment by 
sharp dissection and pinning out flat in the Petri dish with the mucosal side uppermost.  Care was 
taken to maintain knowledge of the orientation of circular and longitudinal axis of the tissue for 
subsequent strip preparation.  
 
 
2.2 Strip Preparation 
Strips destined for recordings of contractile behavior were tied at both ends with surgical 
silk – on one end a simple loop for attachment to a glass hook, the other end to a length of silk 
tied to a brass ring. Some strips were left intact while others had their mucosa gently scraped off. 
In order to differentiate between the longitudinal muscle and the circular muscle without directly 
removing them from the strip in order to preserve muscle integrity, strips were tied and hung in 
an orientation where force transduction was only in the direction of the desired muscle type. To 
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measure circular muscle contraction, the strip was orientated such that the direction circular 
muscle runs along the colon would be placed vertically within the bath so the transducer would 
only respond to contractions in that particular direction. The same was performed with 
longitudinal muscle measurements. The strip was then placed in a vertical orientation with the 
loop secured to a glass hook and the brass ring to a FT-03C Force Transducer (Grass 
Instruments, East Warwick, RI). An organ bath (Radnoti, Monrovia, CA) was raised to submerge 
the strip in 5 mL of continuously oxygenated and warmed Krebs solution. Force recordings were 
amplified by an Octal Bridge Amplifier (AD Instruments, Colorado Springs, CO), relayed to a 
Powerlab 8/35 with Grass Adaptor Unit and displayed by a PC running LabChart Pro7 (AD 
Instruments, Colorado Springs, CO). Force was recorded in grams and raw value data was able 
to be retrieved and exported into Microsoft Excel for further analysis.  
Strips destined for molecular assay were treated as those intended for recordings until the 
pinning procedure. Selected distal colon strips had their mucosa removed and were preserved but 
separated into different tubes. A whole tissue strip was also isolated and kept in a micro-
centrifuge tube. This same process was repeated for proximal colon strips as well. Tissue 
samples were placed into TPER (Tissue Protein Extraction Reagent, Pierce, and Rockford, IL) 
lysis buffer. Into each vehicle, a protease/phosphatase cocktail (100 g/mL PMSF, 10 g/mL 
leupeptin, 30 mM sodium fluoride and 3 mM sodium vanadate) was added at a concentration of 
2 µL/mL. Tissue was homogenized and solubilized in the above solutions. Following 
centrifugation at 14000 g for 15 min at 4°C, the supernatant was removed and prepared for 
Western Blot Analysis. 
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2.3 Force Measurement 
Force experiments were conducted in the following manner. Following hanging of the 
strip and submersion in the organ bath filled with warm oxygenated Krebs solution, strips were 
subjected to 1 gram of pre-tension. Strips were allowed to equilibrate for no less than 45 minutes 
during which the strips were washed at 15 min intervals before experiments were conducted and 
data collected. Exposure to Neurotensin, antagonists, and KCl occurred within the organ bath. 
Concentrations were determined from preliminary experiments or from published articles and 
were in agreement with current literature and are noted in the results.  
Following an experiment, strip data were reviewed and analyzed from within the 
LabChart 7 software suite. Experiments were designed to compare treatment to control 
conditions with each strips serving as its own control. Paired t-tests were conducted in Prism 6 
(GraphPad Software, La Jolla, CA), and significance set at P < 0.05. The dose-response curve 
obtained was subject to ANOVA via Prism. 
 
 
2.4 Data Analysis 
 Contractile data was viewed from several perspectives as to determine the dose-response 
effect of Neurotensin and to characterize the effect of Neurotensin on the distal rat colon in the 
presence of the NT1 and NT2 receptor antagonists: changes in phasic contraction and changes in 
tonic contraction (basal tone) were noted. Measurements were taken over a course of 90 seconds 
prior to administration of any drug and 90 seconds after administration of a drug (or in the case 
of measuring change in basal tone, measurement at plateau within 90 seconds). After every 
application of drug, a minimum of an hour washout period was used with 15 minutes in between 
washes of warmed oxygenated Krebs in concordance with previous literature obtained in other 
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regions of the small and large intestine in order to minimize receptor desensitization (Mule 
1996). Our preliminary studies (data not shown) confirmed that this was necessary to obtain 
reproducible contractions to Neurotensin and to avoid desensitization. Once raw values were 
retrieved, calculations of percent change and statistical analysis were performed in Prism 6 
(GraphPad Software, La Jolla, CA).  
 Dose Response curves were analyzed via one sample one tail t-tests (P<0.05 for 
significance) and reported as percent change +/- Standard Error of the Mean. Inhibitor 
experiments were analyzed via two tailed t-tests (P<0.05 for significance).  
 
 
2.5 Phasic Contraction 
 Phasic contraction was measured as the average difference between the cyclic maxima 
and minima in the selected cycles. For the studied 90 second interval, the difference was 
calculated between the peak of a contraction and minima of contraction and these values were 
averaged over the 90 second interval. Such measurements were made in multiple strips from 
multiple animals and paired t-tests conducted to determine if a difference was significant.  
 
 
2.6 Tonic Contraction 
 Tonic contraction was determined by measuring the change in basal tone of the muscle 
strip and was accomplished by calculating the mean of the basal tonic level upon which phasic 
contractions were superimposed within the studied 90 second intervals. The intent of the 
experiment was to observe percent changes in basal tone, measured before and after treatment 
with Neurotensin in the presence or absence of receptor antagonists.  
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2.7 Western Blot Analysis 
To determine the amount and molecular size of proteins present in a sample, Western 
Blotting was used. Cell lysates were prepared and electrophoresed on a 1.5 mm thick 
12%  Tris/glycine SDS-polyacrylamide gel containing 0.1% SDS (?) for 1.5 hours at 110V in 1X 
SDS-PAGE running buffer (20mM Tris-glycine pH 8.3, 100mM NaCl, 70mM EDTA, 2% (w/v) 
SDS). Proteins were then transferred to a Nitrocellulose transfer membrane (BioRad, Hercules 
CA) overnight in 1X transfer buffer (20mM Tris-HCl pH 7.9, 100mM NaCl, 70mM EDTA, 20% 
MeOH).  
Following transfer, membranes were washed three times in TBS (10 mM Tris HCl pH 
7.6, 150 mM NaCl) supplemented with 0.5% Tween 20 for 15 minutes each then incubated in 
blocking buffer (5% non-fat dried milk in TBS-T) for one hour on a shaker before incubating 
overnight at 4˚C in primary antibody recognizing a specific target protein (Table 3) diluted in 
blocking buffer. Membranes were then washed as before in TBS-T and bound antibody was 
detected by 1 hour incubation at room temperature with the appropriate IRDye secondary 
antibody (Table 2) diluted in blocking buffer. The interaction of the primary and secondary 
antibodies was detected and imaged using ODYSSEY Infrared Imaging System (LI-COR 
Biotechnology, Lincoln NE) 
 
 
 
Primary Antibody Dilution Secondary Antibody 
NT1 Monoclonal: sc-7596  1:1,000 Anti-mouse 
NT2 Polyclonal sc-6243 1:1,000 Anti-rabbit 
Table #2. Antibodies for Western Blot. All antibodies were obtained from Sigma-
Aldrich (St. Louis, MO).  
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Results 
 
 
 
 
3.1 Contractile Response in Circular and Longitudinal Muscle 
Sample traces are presented to demonstrate the variety of contraction waveforms and 
responses to Neurotensin. Contractions may exhibit phasic activity superimposed upon the 
described waveforms. N is designated as the number of unique strips used. Strips of the distal rat 
colon were exposed to Neurotensin at concentrations of 10−9 M, 10−8 M, 10−7 M, and 10−6 M in 
order to produce a dose-response curve. Longitudinal and circular muscle strips were 
differentiated as described in the methods section. Because circular muscle strips and 
longitudinal muscle strips responded in the same manner to varying doses of Neurotensin and as 
the circular muscle is the dominant force to propulsive activity within the gut as cited in the 
introduction, circular muscle was used for the rest of the experiments. When the mucosa is intact, 
muscular strips exposed to Neurotensin responded with an inhibitory effect to its phasic activity. 
When the mucosa is removed, there tended to not be a major change in phasic activity due to 
Neurotensin, but an increase in basal tone (tonic activity) was observed regardless if the strip was 
longitudinal or circular muscle. An example of the similarities in response to Neurotensin in 
circular and longitudinal muscle strips of distal rat colon with the mucosa intact is shown in 
Figure #2.  
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Figure #2: Circular and Longitudinal Muscle Tracings with Mucosa Intact 
         
        The first tracing is a sample tracing of Circular muscle with the mucosa intact from the 
distal rat colon and the second tracing is longitudinal muscle also with mucosa intact from the 
distal rat colon. Dotted vertical line indicates addition of 10−6 M Neurotensin followed by the 
inhibitory response of the muscle strip. The Y-axis is in grams force and the X-axis is time in 20 
second intervals.  
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3.2 Differences in Mucosa Intact and Mucosa Removed 
        From here, all muscle strips are of circular muscle unless otherwise noted. Circular muscle 
with mucosa intact tended to have more pronounced and frequent phasic activity as opposed to 
strips with their mucosa removed. Likewise, strips with their mucosa intact tended to respond to 
Neurotensin by attenuating phasic activity but having a minimal effect on tonic activity, but 
strips with their mucosa removed tended to not have their phasic activity affected in response to 
Neurotensin but had an increase in tonic contractile activity. An example of the difference 
between the effect of Neurotensin on circular muscle tissue with the mucosa intact and their 
mucosa removed is shown in Figure #3. Table #3 summarizes this pattern as well and data 
analysis on this finding follows the tracings.  
 
 
 
 
 
Phasic Contraction Tonic Contraction 
Circular Muscle (+) Mucosa ↓ - 
Circular Muscle (-) Mucosa - ↑ 
Table #3. Summary of Neurotensin Effects.  Summary of rat distal colon preparations’ 
with (+) and without (-) mucosa, responses to Neurotensin  
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Figure #3: Mucosa Intact Versus Mucosa Removed Muscle Tracings 
         
        The first tracing is a sample tracing of Circular muscle with the mucosa intact from the 
distal rat colon and the second tracing is Circular muscle with mucosa removed from the distal 
rat colon. Dotted vertical line indicates addition of 10−6 M Neurotensin followed by the 
inhibitory response of the muscle strip in the mucosa intact strip and the contractile response in 
the mucosa removed strip.	  The Y-axis is in grams force and the X-axis is time in 20 second 
intervals. 
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3.3 Data Analysis of Dose Response of Neurotensin Measuring Phasic Change 
The responses of varying doses of Neurotensin were observed in the distal rat colon in 
two preparations. A one sample t-test was performed (P<0.05 for significance) for all dose-
response graphs. All strips serve as their own individual controls for the experimental treatments 
and all statistical tests are suitably conducted on repeated measurements. Strips were incubated 
in Neurotensin for no more than two minutes and then washed out with warm Krebs solution 
because preliminary studies demonstrated a tendency of Neurotensin to cause desensitization 
with prolonged exposure. This procedure was repeated with strips with their mucosa intact as 
mentioned in detail in the Methods section. For experiments performed with their mucosa intact, 
inhibitory responses were a mean of -2.63% ± 6.12% (n=7, 2 rats) at 10−9 M concentration of 
Neurotensin,  -13.17% ± 4.78% (n=8, 2 rats) at 10−8 M concentration of Neurotensin, -22.25% ± 
5.16% (n=28, 5 rats) at 10−7 M concentration of Neurotensin, and -32.34% ± 4.87% (n=44, 9 rats) 
at 10−6 M  concentration of Neurotensin (Figure 4). The Neurotensin doses ranging from 10−6 M to 
10−8 M were found to be statistically significant (P<0.05).  
For experiments performed with their mucosa removed, percent change of phasic activity 
was a mean of -0.67% ± 2.63% (n=8, 2 rats) at 10−9 M concentration of Neurotensin,  -4.69% ± 
1.66% (n=8, 2 rats) at 10−8 M concentration of Neurotensin, -3.84% ± 2.83 (n=28, 5 rats) at 10−7 M 
concentration of Neurotensin, and -7.65% ± 2.59% (n=44, 9 rats) at 10−6 M  concentration of 
Neurotensin (Figure 5). Although all responses were minimal and not likely to be biologically 
significant, the Neurotensin doses 10−8M and 10−6 M were found to be statistically significant 
(P<0.05). 
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Figure #4: Dose-Response of Phasic Changes in response to Neurotensin with Mucosa 
Intact 
         
        Sample size for 10−9 M Neurotensin (n=7, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7 M 
Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats) 
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Figure #5: Dose-Response of Phasic Changes in response to Neurotensin with Mucosa 
Removed 
         
        Sample size for 10−9 M Neurotensin (n=8, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7 M 
Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats) 
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3.4 Dose Response of Neurotensin Measuring Tonic Change 
         
While phasic changes were noted in response to Neurotensin as described above, strips 
also exhibited changes in their basal tone either in addition to or excluding changes in phasic 
activity. Similar to the previous experiment, the contractile responses of distal rat colon to 
varying doses of Neurotensin, specifically the changes in basal tone, were measured. The strips 
were exposed to Neurotensin for no more than 2 minutes as indicated in the methods section. For 
experiments performed with their mucosa intact, percent change in basal tone was a mean of -
1.04% ± 1.22% (n=8, 2 rats) at 10−9 M concentration of Neurotensin,  -6.73% ± 1.51% (n=8, 2 
rats) at 10−8 M concentration of Neurotensin, -8.89% ± 1.87% (n=28, 5 rats) at 10−7 M 
concentration of Neurotensin, and -6.03% ± 2.25% (n=44, 9 rats) at 10−6 M  concentration of 
Neurotensin (Figure 6). These force measurements were found to be statistically significant 
(P<0.05) for doses ranging from 10−6 M to 10−8 M according to a one sample t-test. It is 
noteworthy that for these strips there was an inhibition of tone which paralleled the effect of 
Neurotensin on phasic activity in these strips.  Even though reaching statistical significance, the 
response was however relatively small compared to the inhibition of phasic activity.  
For experiments performed with their mucosa removed, percent change of tonic 
contraction was a mean of -0.79% ± 0.32% (n=8, 2 rats) at 10−9 M concentration of 
Neurotensin,  -0.95 ± 0.48% (n=8, 2 rats) at 10−8 M concentration of Neurotensin, 0.97% ± 2.11 
(n=28, 5 rats) at 10−7 M concentration of Neurotensin, and 12.90% ± 3.28% (n=44, 9 rats) at 10−6 
M  concentration of Neurotensin (Figure 7). According to a one sample t-test, the 10−6 M dose of 
Neurotensin was statistically significant (P<0.05).  
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Figure #6: Dose-Response of Tonic Changes in response to Neurotensin with Mucosa Intact 
         
        Sample size for 10−9 M Neurotensin (n=8, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7 
M Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats) 
40	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
41	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure #7: Dose-Response of Tonic Changes in response to Neurotensin with Mucosa 
Removed 
         
        Sample size for 10−9 M Neurotensin (n=8, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7 
M Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats) 
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3.5 Effects of NT1 Receptor Antagonism 
         
        The effects of Neurotensin has been shown to be mediated by the NT1 and NT2 receptors in 
a variety of other tissues, but the role of these receptors in the distal rat colon have not been 
thoroughly characterized.. All strips were from distal rat colon and were subjected to 10−6 M 
concentration of SR 48692, a well-known selective inhibitor of the NT1 receptor, for 10 minutes 
prior to incubation with 10−6 M Neurotensin in a variety of strip preparations to observe the 
changes in phasic or tonic activity of these muscle strips in response to Neurotensin. A 
concentration of 10−6 M of SR 48692 and 10 minute exposure was used in concordance with 
previous literature utilizing similar methods of strip preparation. Addition of SR 48692 alone had 
no effect on tonic or phasic activity of the muscle strips. 
 We first measured percent changes in phasic activity due to treatment. Incubation with 
10−6 M Neurotensin with the mucosa intact caused a mean percent change of -37.84% ± 
11.41%(n=8, 4 rats) and incubation of Neurotensin and the inhibitor lead to a mean percent 
change of -36.26% ± 10.72% (n=8, 4 rats). The same incubation with the mucosa removed 
caused a mean percent change of -6.17% ± 4.10 (n=8, 4 rats) while incubation of the inhibitor 
with Neurotensin caused a mean percent change of -5.13% ± 2.44% (n=8, 4 rats). There were no 
statistically significant changes to phasic contraction with the inhibitor with mucosa intact or 
removed (all P > 0.05, n=8 from 4 animals). Data was analyzed by a paired two-tailed t-test 
(P<0.05 to achieve significance). Results are summarized in Figure 8 and 9.  
        Next, we repeated the above experiment but measured percent changes in tonic 
contraction. Incubation with 10−6 M Neurotensin with the mucosa intact caused a mean percent 
change of -5.47% ± 2.10% (n=8, 4 rats) and incubation of Neurotensin and the inhibitor lead to a 
mean percent change of -4.90% ± 2.58% (n=8, 4 rats) . The same incubation with the mucosa 
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removed caused a mean percent change of 4.22% ± 1.65% (n=8, 4 rats) while incubation of the 
inhibitor with Neurotensin caused a mean percent change of 4.88% ± 2.19% (n=8, 4 rats). There 
were no statistically significant changes to tonic contraction with the inhibitor in mucosa intact 
or removed (all P > 0.05, n=8 from 4 animals). Data was analyzed by a paired two-tailed t-test 
(P<0.05 to achieve significance). Results are summarized in Figure 10 and 11.  
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Figure #8: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Phasic 
Contraction with Mucosa Intact 
         
        Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M 
SR48692 inhibitor (n=8, 4 rats) 
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Figure #9: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Phasic 
Contraction with Mucosa Removed 
         
        Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M SR48692 
inhibitor (n=8, 4 rats) 
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Figure #10: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Tonic 
Contraction with Mucosa Intact 
         
        Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M 
SR48692 inhibitor (n=8, 4 rats) 
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Figure #11: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Tonic 
Contraction with Mucosa Removed 
         
        Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M 
SR48692 inhibitor (n=8, 4 rats) 
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3.6 Effects of Nonselective Receptor Antagonism 
Since the NT1 antagonist did not significantly affect the response to Neurotensin, the 
effect of a non-selective Neurotensin receptor antagonist, SR-142,948, was next tested on the 
effect of Neurotensin on the muscle strips. All strips were from distal rat colon and were 
subjected to 10−6 M concentration of SR-142,948, a non-peptide and non-selective inhibitor of 
the Neurotensin receptors for 10 minutes prior to incubation with 10−7 M Neurotensin and 10−6 M 
Neurotensin in a variety of strip preparations to observe the changes in phasic or tonic activity of 
these muscle strips in response to Neurotensin. The nonselective antagonist added to the strips 
alone had no effect on the basal tone or phasic contractions by itself. The 10−6 M concentration 
of SR-142,948 was used in concordance with literature performing similar experiments (Croci et 
al 1999). We first measured percent changes in phasic activity due to treatment. Incubation with 
10−7 M and 10−6 M Neurotensin with the mucosa intact caused a mean percent change of -31.65% 
± 10.29% (n=12, 4 animals) and -43.43% ± 10.76% (n=12, 4 animals) respectively. Incubation of 
10−7 M Neurotensin and the inhibitor lead to a mean percent change of -1.41% ± 3.53% (n=12, 4 
animals). After, 10−6 M Neurotensin was added to the bath  the mean percent change of phasic 
contraction was -4.59% ± 3.91% (n=12, 4 animals).  The same incubation procedure with the 
mucosa removed caused a mean percent change of -3.78% ± 3.21 (n=12, 4 animals) with 10−7 M 
Neurotensin and -9.66% ± 6.24% (n=12, 4 animals) with 10−6 M Neurotensin. Incubation of the 
inhibitor and 10−7 M Neurotensin caused a mean percent change of -1.05% ± 1.38% (n=12, 4 
animals). After 10−6 M Neurotensin was added to the bath the mean percent change of phasic 
contraction was -0.91% ± 1.14% (n=12, 4 animals). The strips incubated in the 10−7 M 
Neurotensin treatment and the strips incubated in the 10−7 M Neurotensin treatment with the 
inhibitor were significantly different when the mucosa was intact. Likewise, The strips incubated 
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in the 10−6 M Neurotensin treatment and the strips incubated in the 10−6 M Neurotensin treatment 
with the inhibitor were significantly different when the mucosa was intact(P < 0.05, n=12 from 4 
animals). Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve significance). There 
was no significant difference with the inhibitor when the mucosa was removed. Results are 
summarized in Figure 12 and 13.  
We repeated the above experiment but measured percent changes in tonic contraction 
instead of phasic contraction. Incubation with 10−7 M and 10−6 M Neurotensin with the mucosa 
intact caused a mean percent change of -12.00% ± 3.72% (n=12, 4 animals) and -17.60% ± 
6.56% (n=12, 4 animals) respectively. Incubation of 10−7 M Neurotensin and the inhibitor lead to 
a mean percent change of 1.08% ± 1.25% (n=12, 4 animals). After 2 minutes, 10−6 M 
Neurotensin was added to the bath without washing out the bath and the mean percent change of 
phasic contraction was 3.25% ± 1.84% (n=12, 4 animals).  The same incubation procedure with 
the mucosa removed caused a mean percent change of 2.41% ± 4.59(n=12, 4 animals) with 10−7 
M Neurotensin and 27.29% ± 8.77% (n=12, 4 animals) with 10−6 M Neurotensin. Incubation of 
the inhibitor and 10−7 M Neurotensin caused a mean percent change of 0.58% ± 0.56% (n=12, 4 
animals). After 2 minutes, 10−6 M Neurotensin was added to the bath without washing out the 
bath and the mean percent change of tonic contraction was 0.46% ± 0.97% (n=12, 4 animals). 
The strips incubated in the Neurotensin treatment and the strips incubated in the Neurotensin 
treatment with the inhibitor were significantly different when the mucosa was intact (P < 0.05, 
n=12 from 4 animals). When the mucosa was removed, the data was only significant for the 10−6 
M Neurotensin and the inhibitor (P < 0.05, n=12 from 4 animals).  Data was analyzed by a paired 
two-tailed t-test (P<0.05 to achieve significance). Results are summarized in Figure 14 and 15 
55	  
	  
 
 
 
. 
 
 
 
 
 
 
 
 
Figure #12: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist 
on Phasic Contraction with Mucosa Intact 
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats), 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin + 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).  
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Figure #13: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist 
on Phasic Contraction with Mucosa Removed 
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats), 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin + 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).  
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Figure #14: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist 
on Tonic Contraction with Mucosa Intact 
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats), 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin + 
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).  
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Figure #15: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist on 
Tonic Contraction with Mucosa Removed 
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats), 10−7 
M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin + 10−7 M 
Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).  
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3.7 Effects of NT2 Receptor Antagonism 
         
 Exposure of muscle strips to a selective NT2 antagonist in the same manner as the 
previous experiment was performed next. Since the NT1 antagonist had no effect on the response 
to Neurotensin and the nonselective antagonist was effective, we used this NT2 antagonist to 
confirm that the effects of Neurotensin were mediated by the NT2 receptors. All strips were from 
distal rat colon and were subjected to 10−5 M concentration of Levocabastine, a well-known 
potent and selective inhibitor of the NT2 receptor for 10 minutes prior to incubation with 10−6 M 
Neurotensin in a variety of strip preparations to observe the changes in phasic or tonic activity of 
these muscle strips in response to Neurotensin.  The NT2 receptor antagonist added to the strips 
alone had no effect on basal tone or phasic activity by itself. The 10−5 M concentration of 
Levocabastine was used in concordance with literature performing similar experiments in muscle 
strips (Croci et all 1999). We first measured percent changes in phasic activity due to treatment. 
Incubation with 10−6 M Neurotensin with the mucosa intact caused a mean percent change of -
31.73% ± 7.70% (n=16, 6 rats) and incubation of Neurotensin and the inhibitor lead to a mean 
percent change of -9.37% ± 4.14% (n=16, 6 rats). The same incubation with the mucosa removed 
caused a mean percent change of -3.38% ± 1.02 (n=16, 6 rats) while incubation of the inhibitor 
with Neurotensin caused a mean percent change of 0.20% ± 0.70% (n=16, 6 rats). The strips 
incubated in the Neurotensin treatment and the strips incubated in the Neurotensin treatment with 
the inhibitor were significantly different when the mucosa was both intact and removed (P < 
0.05, n=16 from 6 animals). Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve 
significance). Results are summarized in Figure 16 and 17.  
        We repeated the above experiment but measured percent changes in tonic contraction 
instead of phasic contraction. Incubation with 10−6 M Neurotensin with the mucosa intact caused 
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a mean percent change of -0.13% ± 1.16% (n=16, 6 rats) and incubation of Neurotensin and the 
inhibitor lead to a mean percent change of -1.85% ± 0.66% (n=16, 6 rats) . The same incubation 
with the mucosa removed caused a mean percent change of 13.00% ± 3.83 (n=16, 6 rats) while 
incubation of the inhibitor with Neurotensin caused a mean percent change of -2.54% ± 0.60% 
(n=16, 6 rats). With the mucosa intact, there was no significant difference between the 
Neurotensin treated strips and the Neurotensin with NT2 inhibitor strips (P > 0.05, n=16 from 6 
animals). However, when the mucosa was removed, there was a significant difference between 
the Neurotensin treated strips and the Neurotensin with NT2 inhibitor strips (P < 0.05, n=16 from 
6 animals). The Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve significance). 
Results are summarized in Figure 18 and 19.  
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Figure #16: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Phasic 
Contraction with Mucosa Intact 
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M 
Levocabastine inhibitor (n=16, 6 rats) 
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Figure #17: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Phasic 
Contraction with Mucosa Removed 
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M 
Levocabastine inhibitor (n=16, 6 rats) 
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Figure #18: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Tonic 
Contraction with Mucosa Intact 
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M 
Levocabastine inhibitor (n=16, 6 rats) 
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Figure #19: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Tonic 
Contraction with Mucosa Removed 
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M 
Levocabastine inhibitor (n=16, 6 rats) 
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3.8 Existence of NT2 Receptor 
         
        To determine the existence of the NT1 and NT2 receptor within the distal rat colon and to 
see how this compares in the proximal rat colon, where previous published data have shown 
these receptors to be expressed, a western blot was performed on cell lysates from 6 different 
strip preparations: intact proximal rat colon, the mucosa of the proximal rat colon, proximal rat 
colon with the mucosa removed, intact distal rat colon, the mucosa of the distal rat colon, and 
distal rat colon with the mucosa removed. Figure 20 shows the clear existence of the NT2 
receptor across all strip preparations. The existence of the NT1 receptor is also shown to be in all 
strip preparations.  
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Figure #20: Western Blot for NT2 Receptor in Rat Proximal and Distal Colon 
NT2 Receptor expression in Rat proximal and Rat distal colon were measured in varying 
tissue preparations. Lane 1 represents solely the mucosa of rat proximal colon. Lane 2 represents 
solely the muscle strip with the mucosa removed of the rat proximal colon. Lane 3 represents the 
full intact strip of rat proximal colon. Lane 4 represents solely the mucosa of rat distal colon. 
Lane 5 represents solely the muscle strip with the mucosa removed of the rat distal colon. Lane 6 
represents the full intact strip of rat distal colon.  
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Discussion	  
 
 
 
4.1 Importance of Circular Muscle 
 It was evident early on throughout the experiments that circular muscle and longitudinal 
muscle tended to retain almost identical waveform characteristics. This makes sense logically 
from a physiological perspective since circular muscle causes the intestinal contents to propel 
further down the gastrointestinal tract whereas longitudinal muscle causes the intestine to bunch 
together. Seeing as longitudinal muscle strips and circular muscle strips responded the same to 
Neurotensin and circular muscle is more vital in performing the main function of the gut, circular 
muscle became the focus of our study. The similarities in waveforms and similarities in response 
to Neurotensin is evident in Figure 2.  
  
4.2 Dose Response 
As mentioned in the introduction, the enteric nervous system works to control the gut 
through the release of specific neurotransmitters at specific sites such as mucosal secretory cells. 
While neurotransmitters may be released from these sites, they may function by binding to 
receptors at any of the multitude of layers of the gut. Thus, it was of our labs interest to examine 
how Neurotensin was to affect the muscle with or without the presence of the mucosa. A dose 
response relationship was used to see how different levels of Neurotensin concentration would 
affect the various muscle conditions. 
Phasic changes within muscle strips with the mucosa intact in response to Neurotensin 
lead to a clear trend in inhibition. As the dose of Neurotensin increased, the percent decrease in 
phasic contraction increased. It is possible that the mucosa in the distal colon contains secretory 
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or enteroendocrine cells that respond to Neurotensin by releasing inhibitory neurotransmitters, or 
paracrine agents. It would not be surprising if Neurotensin itself binds to receptors on the mucosa 
or on the muscle fiber itself to directly inhibit phasic activity. For future studies, it would be 
useful to observe the same effects of Neurotensin without neural input by using tetrodotoxin 
(TTX). TTX acts to inhibit any affected nerve cells from firing by blocking the sodium channels 
which mediate the action potential. When the mucosa was removed, concentrations of 10−8 M and 
10−6 M proved to be statistically significant, but in observing the trends, the responses were 
minimal and virtually identical. With the highest concentration leading to a 7.65% decrease, the 
changes looked to be biologically irrelevant.  
While there were changes in the phasic activity of the waveforms, Neurotensin also 
elicited changes in basal tone, also termed tonic activity. We analyzed tonic changes in order to 
see if Neurotensin’s effects on muscle strips were limited to changes in phasic activity. With the 
mucosa intact, concentrations of Neurotensin at 10−8 M, 10−7 M, 10−6 M were all found to be 
significantly different from baseline, but just as in the previous graph, the changes were minimal 
and biologically irrelevant as can be seen in the trend on the graph in Figure 3. When the mucosa 
was removed, it took a 10−6 M concentration to elicit a significant response. This increase in 
basal tone when the mucosa was removed was indicative of the responses seen visually in figure 
3. The biphasic shape was very common in other studies as well (Ohashi 1994) (Fontaine et al 
1985) that used similar preparations. This reinforces our earlier thoughts of the mucosa having 
some inhibitory neuropeptides released in response to Neurotensin. Since there is a contractile 
effect when the mucosa removed (albeit a tonic contraction), it would indicate that there would 
be receptors on the muscle itself and this response leads to either a direct increase in contraction 
or a release of excitatory neurotransmitters. A summary of these results is seen in table 3. In 
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every case, a 10−6 M dose of Neurotensin elicited the best response and would be the dose used in 
every receptor study to follow.  We did not try higher concentrations of Neurotensin because this 
would be too expensive given the amount necessary for use in our 5 ml tissue baths. 
 
 
4.3 NT1 Receptor  
As noted in the introduction, previous studies indicate that the NT1 receptor is more 
responsive and has a higher affinity to Neurotensin than the NT2 receptor (Mazzella 1999). The 
NT2 receptor retains a 10-fold lower affinity to Neurotensin than the NT1 receptor (Schotte et al 
1986). We decided to identify which receptors mediated the responses in our dose response 
curves. First we used a NT1 receptor, SR 48692, to determine if the phasic and tonic changes we 
observed in the different muscle conditions would be affected by inhibition of the NT1 receptor. 
Our results show that there was not a significant difference in the Neurotensin induced changes 
in phasic and tonic activity between those treated with 10−6 M Neurotensin and 10−6 M 
Neurotensin with the inhibitor. This would indicate that the effects observed were not mediated 
through the NT1 receptor. Although previous studies were not performed in the rat distal colon, 
this was contrary to what was seen in proximal colon, the brain, and other regions of the gut in 
many animals (Pettibone 2002). This would indicate that the rat colon is unique in its response. 
Our studies with the NT1 antagonist alone also showed no effect on the basal phasic activity or 
tonic activity. This suggests that there is no release of endogenous NT acting through NT1 
receptors to modulate activity in the absence of stimulation.  
As this is a physiological functional study, future studies should be done to examine 
whether this is due to a difference in the ratio of Neurotensin receptors or if this is due to 
differences in downstream mediators of the receptors. Pharmacological and biochemical studies 
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have indicated that the NT1 receptor is coupled to cGMP, cAMP, and inositol phosphate 
signaling cascades (Hermans 1998) (Vincent et al 1999). It would be helpful to see if this 
mechanism is the same mechanism is responsible for the physiological responses observed in the 
distal rat colon.  
 
 
4.4 Non-selective Inhibitor 
A non-selective inhibitor was used in separate studies following the completion of the 
studies with the NT1 selective inhibitor in order to elucidate if Neurotensin effects could be 
inhibited at all by blockade of NT receptors. The changes in phasic contraction with the mucosa 
intact and removed due to Neurotensin were observed to be almost completely inhibited with the 
introduction of the nonselective inhibitor. Phasic contraction when the mucosa was removed did 
not show significant difference but just like in the previous experiments, phasic contractions with 
the mucosa removed produced little to no change in the first place so it is not unreasonable to not 
see much change when incubated with the inhibitor. Tonic contraction with the mucosa removed 
only showed significance when the Neurotensin dose of 10−6 M was used. This is also not too 
surprising since a 10−6 M dose was required to elicit a significant response in tonic contraction 
with the mucosa removed in the first place. When the nonselective antagonist was tested against 
the 10−6 dose of Neurotensin, it caused a significant inhibition. Since this antagonist does not 
distinguish between NT1 and NT2 receptors and since the selective NT1 receptor antagonist had 
no effect, this suggested that the NT2 receptor could be the main mediator of the response.  This 
idea was tested in the next set of experiments. It should be noted that the non-selective antagonist 
had no effect on basal phasic activity or basal tone when added alone.  As described above, we 
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interpret this to mean that there is no basal, unstimulated release of Neurotensin that is modifying 
the basal contractile activity of the colonic muscle. 
 
 
4.5 NT2 Receptor 
From these results it would seem that the NT2 receptor is the main mediator in the effects 
elicited by Neurotensin, but we used a NT2 selective inhibitor to confirm this. Phasic and tonic 
Neurotensin induced changes with and without the mucosa intact were significantly inhibited by 
the NT2 selective inhibitor. As with the other antagonists, the selective NT2 antagonist had no 
effect on basal phasic activity or basal tone when added alone. This confirms the notion that 
there is no basal, unstimulated release of Neurotensin that is modifying the basal contractile 
activity of the colonic muscle. 
The findings of the selective NT2 receptor antagonist, in conjunction with the findings 
with the non-selective inhibitor, supports the idea that the effects of Neurotensin on the rat distal 
colon are mediated by the NT2 receptor. The results with the non-selective antagonists are 
particularly important because if there were other receptors outside of these receptors, the 
nonselective receptor inhibitor would likely not have abolished all the effects of Neurotensin that 
were observed.  One factor we considered as a confounding influence was the sortilin receptor, 
also known as the NT3 receptor, since it binds Neurotensin. In studies in a variety of tissues, this 
NT3/sortilin receptor has been found to make multimers with other receptors such as the TrkB 
receptor to change its affinity or selectivity (Nykjaer 2012). The NT3/sortilin receptor has 
normally been thought of in this way or as a clearance receptor because it does not couple to a 
signaling pathway in most tissues. Only very recently, have reports begun to suggest that in some 
tissues there is a more complex role of the NT3/sortilin receptor. Considering that there is no 
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specific antagonist of this receptor, the current thinking that this is a non-signaling receptor, and 
the strong effects of the NT2 selective and the NT1-NT2 nonselective antagonist, we concluded 
that the effects of Neurotensin we observed were mediated by the NT2 receptor. 
It is also important to note that there have been doubts cast regarding the agonistic 
properties of Neurotensin at this site and subsequently, doubts as to whether this receptor can be 
truly regarded as a true Neurotensin receptor (Gendron 2004). In CHO cells stably transfected 
with human NT2 receptor, SR48692, but neither Neurotensin nor levocabastine, was found to 
activate classic second messenger systems, such as phosphoinositide hydrolysis, Ca2+ 
mobilization, or ERK1/2 phosphorylation. (Vita et al 1998) (Richard et al 2001). This would 
suggest that the Neurotensin receptor either itself differs somehow in function from the same 
receptor found in rodents, or is mediated through different signaling mechanisms. With the 
possibility that rodent NT2 receptors function differently than human receptor, our findings 
support this idea.  
 
 
4.6 Existence of the NT2 Receptor 
 To confirm the physiological and pharmacological evidence for the action and presence 
of an NT2 receptor in the rat distal colon, we turned to a molecular approach.   Western Blot 
results indicate that the NT2 receptor was found in the mucosa, the muscle, and in the intact 
distal rat colon. With the receptor located in both the muscle and the mucosa, it makes sense that 
regardless whether the mucosa was intact or not, an effect was observed. Previous studies have 
suggested that the NT2 receptor is absent in the colon of rats (Pettibone 2002) but our results 
contradict those claims. Other studies claim that the NT2 receptor is scarcely found in the 
periphery but not necessarily absent. It is possible that the rat colon is unique in that the NT2 
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receptor is found there and not in other species, but this would require further studies to be done. 
At the very least, the finding of the NT2 receptor helps strengthen the argument that the NT2 
receptor exists in the distal rat colon and plays an important role in the effects of Neurotensin on 
phasic and tonic contraction. The Western Blot also included samples of the proximal rat colon 
where the NT1 and NT2 receptors were already previously found to exist. This was done to 
confirm the validity of the antibody and shows that the NT2 receptor exists in both sections of 
the colon.  
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4.7 Avenues to Explore 
 To further and strengthen the model, the following experiments are proposed: 
• Downstream mediators of the NT1 and NT2 receptor have been identified in other models and 
must be confirmed to in the rat distal colon 
• If Neurotensin does in fact lead to further excitatory or inhibitory neurotransmitter release, the 
identification of these should be explored 
• Muscarinic antagonism and Na+ channel blockade by TTX to determine neural contributions and 
possible modulation by M2 signaling  
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